In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 5, 1999, Pages 353-363

  Kanzawa, Fumihiko ^a   Nishio, Kazuto ^a   Fukuoka, Kazuya ^a   Sunami, Toshihiko ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

3 D model analysis; Combination effect; KRN5500; Spicamycin analog; Synergism

Indexed keywords

6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; DRUG EFFECT; DRUG POTENTIATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; STREPTOMYCES;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PURINE NUCLEOSIDES; TUMOR CELLS, CULTURED;

EID: 0033021744     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050907     Document Type: Article

References (22)

1. Aszabs A, Lemanski P, Berk B, Dutcher JO (1966) Septacidin analogues. Antimicrob Agents Chemother 1965: 845
2. Burger AM, Kaur G, Hollingshead M, Fischer RT, Nagashima K, Malspeis L, Duncan KLM, Sausville EA (1997) Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression. Clin Cancer Res 3: 455
3. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27
4. DeVita VT Jr (1989) Principles of chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA: (ed) Cancer principles and practice of oncology. JB Lippincott, Philadelphia, p 276
5. Drewinko B, Loo TL, Brown B, Gottlieb JA, Freireich EJ (1976) Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells. Cancer Biochem Biophys 1: 187
6. Gralla RJ, Casper ES, Kelsen DP, Braun DW Jr, Dukeman ME, Martini N, Young CW, Gplbey RB (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 95: 414
7. Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47: 331
8. Hayakawa Y, Nakayama M, Kawai H, Tanabe K, Nakayama H, Shimizu A, Seto H, Otake N (1983) Studies on the differentiation inducers of myeloid leukemia cells III. Spicamycin, a new inducer of differentiation of HL-60 human promyelocytic cells. J Antibiot (Tokyo) 36: 934
9. Hayakawa Y, Nakayama M, Kawai H, Tanabe K, Nakayama H, Shimizu A, Seto H, Otake N (1985) Spicamycin, a new differentiation inducer of mouse myeloid leukemia cells (MI) and human promyelocytic leukemia cells (HL-60). Agric Biol Chem 49: 2685
10. Kamishohara M, Kawai H, Odagawa A, Isoe T, Mochizuki J, Uchida T, Hayakawa Y, Seto H, Tsuruo T, Otake N (1993) Structure-antitumor activity relationship of semi-synthetic spicamycin analogues. J Antibiot (Tokyo) 46: 1439
11. Kamishohara M, Kawai H, Sakai T, Isoe T, Hasegawa K, Mochizuki J, Uchida T, Kataoka S, Yamaki H, Tsuruo T, Otake N (1994) Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells. Oncol Res 6: 383
12. Kanzawa F, Saijo N (1997) In vitro interaction between Gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 24: s7-8
13. Kanzawa F, Nishio K, Kubota N, Saijo N (1995) Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of cell lines, SBC-3/NB. Cancer Res 55: 2806
14. Kanzawa F, Nishio K, Fukuoka K, Fukuda M, Kunimoto T, Saijo N (1997) Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3. Int J Cancer 71: 311
15. Lee Y-S, Nishio K, Ogasawara H, Funayama Y, Ohira T, Saijo N (1995) In vitro cytotoxicity of a novel antitumor antibiotic, Spicamycin derivative, in human lung cancer cell lines. Cancer Res 55: 1075
16. Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3: 285
17. Miller TP (1990) Rationale for the use of chemotherapy in non-small cell lung cancer. Semin Oncol 17: 11
18. Prichard MN, Shipman C Jr (1990) A three-dimensional model to analyze drug-drug interactions. Antiviral Res 14: 181
19. Reece PA, Stafford I, Russell J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5: 304
20. Sasaki Y (1992) Pharmacological approach to the platinum compounds. Jap J Cancer Chemother 19: 456
21. Schinazi RF (1991) Combined chemotherapeutic modalities for viral infections: rationale and clinical potential. In: Chou TC, Rideout DC (eds): Synergism and antagonism in chemotherapy. Academic Press, New York p 109
22. Suhnel J (1990) Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Res 13: 23